Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04868890 · ClinicalTrials.gov registry record · Phase 2
A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19
A Phase 2 study, sponsored by Ampio Pharmaceuticals..
- Terminated
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT04868890: Clinical Trial Phase 2 study, sponsored by Ampio Pharmaceuticals..
NCT04868890 is a Phase 2 study that was terminated before completion, run by Ampio Pharmaceuticals.. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04868890, a Phase 2 study, was terminated before completion, sponsored by Ampio Pharmaceuticals..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is phase II study to evaluate the safety and efficacy of inhaled Ampion in adults with respiratory distress due to COVID-19
Primary Outcome
Change in ordinal scale from baseline through Day 5 and through Day 28. The WHO's 8 point ordinal scale reflects the highest level of support the subject required on the day being recorded. 0 = No clinical or virological evidence of infection; 1 = no limitation of activities; 2 = limitation of activities; 3 = Hospitalized, no oxygen; 4 = Hospitalized, oxygen by mask or nasal prongs; 5 = Hospitalized, non-invasive ventilation or high-flow oxygen, 6 = Hospitalized, mechanical ventilation; 7 = Hosp
Interventions
- OTHER Placebo
- BIOLOGICAL Ampion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2022-04-13 |
| Phase | Phase 2 |
Why NCT04868890 stopped before completion
NCT04868890 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04868890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04868890 about?
NCT04868890 is a clinical study titled "A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19". This is phase II study to evaluate the safety and efficacy of inhaled Ampion in adults with respiratory distress due to COVID-19
What is the current status of trial NCT04868890?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2021-06-22. Estimated completion is 2022-04-13.
What interventions are being tested in trial NCT04868890?
The interventions under investigation include: Placebo (OTHER), Ampion (BIOLOGICAL).
Who is sponsoring clinical trial NCT04868890?
This trial is sponsored by Ampio Pharmaceuticals., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04868890's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI